SparingVision SparingVision

SparingVision to Showcase its Gene-Agnostic Gene Therapy Programs at Upcoming Conferences

SparingVision to Showcase its Gene-Agnostic Gene Therapy Programs at Upcoming Conferences

 

Paris, 28 August 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today

announces that it will showcase its gene-agnostic gene therapy programs, SPVN06 and SPVN20, and research on retinal diseases at upcoming scientific conferences.

Conference and presentation details below:

Podium Presentation Title: SPARINGVISION’s Gene-Agnostic Gene Therapy Approach to Blinding Retinal Diseases
Presenter: Kali Stasi, M.D.; Ph.D.
Session Title: Rapid Fire Panel Discussion
Date and Time:   Sep 4, 2025, 17:40-18:04 Central European Summer Time (CEST)

  • EURETINA (European Society of Retina Specialists), Paris, France – 4-7 September

Podium Presentation Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Presenter: Isabelle Audo, M.D.; Ph.D.
Session Title: Free Paper 2 – Inherited Retinal Diseases
Date and Time:   Sep 4, 2025, 12:00 (CEST)

Podium Presentation Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Presenter: Joseph Martel, M.D.
Session Title: Genetic Diseases, Dystrophies, Degenerations
Date and Time:   Sep 10, 2025, 15:30 Eastern Daylight Time (EDT)

Panel: Gene Agnostic Therapeutic Strategies
Panelist: Kali Stasi, M.D.; Ph.D.
MiniSymposium: Therapeutic Innovations in Inherited Retinal Degenerations
Date and Time:   Sep 12, 2025, 13:30-15:30 (CEST)

Podium Presentation Title: The Need for an Unbiased Assay to Detect and Quantify Replication Competent AAV in Clinical Vector Products

Presenter: Pierre-Axel Vinot, Pharm.D. Ph.D.
Session Title: Gene Therapy Manufacturing & Analytics
Date and Time:   Sep 18, 2025, 11:45-12:15 (EDT)

Podium Presentation Title: Development of SPVN20, a gene therapy for cone reactivation in inherited retinal degeneration
Presenter: Hanen Khabou, Ph.D.
Session Title: CNS & Sensory session
Date and Time:   Oct 7, 2025, 17:00-19:30 (CEST)

 

Poster Presentation Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy

Presenter: Laure Blouin
Poster Number: P0315
Date and Time:   Oct 8, 2025, 14:00 to 15:30 (CEST)

Poster Presentation Title: PRODYGY: Characterization of retinal degeneration in patients with rod-cone dystrophy to inform on potential efficacy endpoints of gene therapy

Presenter: Alice Le Meur
Poster Number: P0368
Date and Time:   Oct 9, 2025, 14:00 to 15:30 (CEST)

**ENDS**

 

NOTES TO EDITORS

Contacts:

Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)

Media: ICR Healthcare (sparingvision@icrhealthcare.com)

 

About SparingVision

SparingVision is a clinical-stage genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for blinding retinal diseases. Its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP) and geographic atrophy secondary to dry-AMD, two leading causes of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.

SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.

Visit www.sparingvision.com for more and follow us on LinkedIn and X  @SparingVision

 

 

© SparingVision